A sustained-release intracanalicular dexamethasone insert (Dextenza) for pediatric cataract surgery

Area of Science:

• Ophthalmology
• Ocular Inflammation
• Pediatric Surgery

Background:

• Postoperative ocular inflammation is a common complication following pediatric cataract surgery.
• Topical steroid eye drops are the standard treatment but require frequent administration and adherence.
• Alternative sustained-release drug delivery methods are being explored to improve outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of a sustained-release intracanalicular dexamethasone insert (Dextenza) for managing postoperative ocular inflammation in children undergoing cataract surgery.

Main Methods:

• A prospective study analyzed 17 eyes of 17 pediatric patients who received the Dextenza insert after cataract surgery.
• Outcomes assessed included anterior chamber inflammation, intraocular pressure, and need for rescue medications.

Main Results:

• The anterior chamber was clear in 18% of eyes at 1-2 weeks post-surgery.
• A spike in intraocular pressure requiring intervention occurred in 18% of eyes.
• Rescue topical steroid treatment was necessary in 29% of eyes.

Conclusions:

• The Dextenza insert demonstrated a potential to reduce or eliminate the need for postoperative topical steroid drops in pediatric cataract surgery.
• While effective, monitoring for intraocular pressure spikes and potential need for rescue therapy remains important.